iCo Therapeutics Inc. (iCo) is a biotechnology company focused on the identification, development and commercialization of drug candidates that treat sight and life threatening diseases. The Company has in-licensed three product candidates: iCo-007, iCo-008 (also known as Bertilimumab), and an oral Amphotericin B delivery system, (Oral AmpB Delivery System) (formerly known as iCo-009). iCo-007 is a second generation antisense compound that reduces levels of a key protein associated with diabetic retinopathy. iCo-008 is a human monoclonal antibody that inhibits the development of severe allergic conjunctivitis, severe asthma, inflammatory bowel diseases and other indications. The oral AmpB Delivery System is for treatment of systemic fungal infections in immune-compromised patients (such as in human immunodeficiency virus/acquired immune deficiency syndrome (HIV/AIDS), cancer, transplant recipients and diabetics) and certain parasitical infections in the developing world.